Reframe Daily—curated by Christin Chong (neuroscience PhD, Buddhist chaplain, healthtech strategy consultant)—delivers optimistic and credible health research updates you won’t find in most popular news outlets, from sources scientists and healthcare providers read and trust.

Today in one sentence: A balance-plus-ear-nerve-stimulation trial helped vestibular-migraine dizziness; a long phase 3 study found lobaplatin chemo held up with fewer toxic effects; an early KRAS vaccine study in pancreatic cancer showed strong immune signals; scientists built a new dengue drug that makes the body break down a virus protein; a nano ultrasound-immune TB treatment worked in early tests; and the FDA opened a new safety review of BHA in foods.

Good news: Adding gentle ear-nerve stimulation to balance exercises helped people with vestibular migraine feel less dizzy and have fewer headaches.

Effects of adding transcutaneous vagus nerve stimulation to vestibular rehabilitation on dizziness and postural control in vestibular migraine: a randomized clinical trial

Market readiness: 🙂🙂🙂🙂 (Uses an existing non-invasive stimulation method plus standard vestibular rehab; needs larger trials and U.S. clearance/coverage for this specific use.)

Good news: A newer platinum chemo (lobaplatin) worked about as well as cisplatin over 10 years, with fewer toxic side effects.

Final survival analysis of induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by concurrent chemoradiotherapy in nasopharyngeal carcinoma: a multicenter, randomized, phase 3 trial

Market readiness: 🙂🙂🙂 (Late-stage randomized trial with long follow-up; would still need U.S. access/approval for lobaplatin to be widely used.)

Good news: In a small first study, a KRAS vaccine plus two immune drugs was mostly mild and sparked strong cancer-fighting T-cell signals in most patients after surgery.

Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial

Market readiness: 🙂🙂 (Early phase I testing in a small group; more trials are needed before routine use.)

Good news: Scientists made a new type of anti-dengue drug that helps the body break down a key virus protein, and it worked across all 4 dengue types in lab tests.

Degraders of the dengue virus capsid protein exhibit differentiated pharmacology relative to capsid inhibitors

Market readiness: 🙂 (Lab-stage drug discovery; not yet tested in people.)

Good news: A new ultrasound-activated nano-treatment helped kill TB germs and may help stop TB from coming back in early tests.

Granulomas microenvironment-guided sono-immunotherapy to treat and prevent recurrence of tuberculosis

Market readiness: 🙂 (Early preclinical research; far from clinic use.)

Good news: The FDA started a fresh safety review of BHA (a food preservative), which could help make packaged foods safer over time.

FDA Launches Assessment of BHA, a Common Food Chemical Preservative

Market readiness: 🙂🙂🙂🙂🙂 (This is an FDA action already in motion; it’s not a new medicine, but it can affect products sold in the U.S.)

Thank you for taking the time to take care of yourself and your loved ones.